CIK 0001517022
- Large accelerated filer
Akebia Therapeutics, Inc.
Sign in to watch- Ticker
- AKBA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208756903
- Phone
- +1 617-871-2098
- Business address
- 180 THIRD AVENUE, FLOOR 2, WALTHAM, MA, 02451
- 4 Open-market buy Director bought 5,000 shares at $11.56 ($57,800)
- 4 Open-market buy Director bought 1,300 shares at $11.82 ($15,365)
- 4 Open-market buy CEO and President bought 1,000 shares at $10.31 ($10,305)
- 4 Open-market buy Director bought 5,000 shares at an average $11.90 ($59,515)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 182,590 shares at $17.00 ($3,104,030)
- 4 Open-market buy Director bought 1,500 shares at $17.00 ($25,500)
- 4 Conversion Chief Medical Officer acquired 29,576 shares (conversion)
- 4 Open-market buy Hadas Nicole R. bought 3,500 shares at $17.00 ($59,500)
Page 18 of 19 · 378 filings